Aktualności
EMA: European Medicines Agency releases best practice guidance on parallel scientific advice with health-technology-assessment bodies
15.05.2014
The European Medicines Agency (EMA) has published for public consultation best practice guidance for pilot parallel scientific advice procedures involving the EMA and health-technology-assessment
...
GMP: EMA issues Draft Guideline on Process Validation for Biotechnological Products - an Analysis
15.05.2014
The draft on process validation for biotechnologically manufactured active pharmaceutical ingredients describes the required data to be submitted for the marketing authorisation or variation of
...
FDA: Guidance for Industry: Stability Testing of Drug Substances and Products, Questions and Answers
15.05.2014
This guidance provides answers to questions from the public comments we received on the draft guidance for industry on NDAs: Stability Testing of Drug Substances and Products (FDA stability
...
EMA: Draft guideline on non-clinical local tolerance testing of medicinal products
08.05.2014
Local tolerance testing is intended to support human exposure to a medicinal product (both active substance and excipient) at contact sites of the body following clinical use. ...
EMA: Draft guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues (Rev 2)
08.05.2014
This guideline lays down the non-clinical and clinical requirements for recombinant insulin-containing products, including human insulin and insulin analogues (both referred to as insulin),
...
EMA: Draft European Union individual case safety report (ICSR) implementation guide
08.05.2014
This guidance specifies the technical requirements and the process of transmission of Individual Case Safety Reports (ICSRs) and is applicable to all stakeholders, which are exchanging ICSRs
...
EMA: Guideline on the role of the pathological Complete Response as an endpoint in neoadjuvant breast cancer studies
08.05.2014
Neoadjuvant chemotherapy is commonly used in locally advanced breast cancer (LABC) patients to facilitate breast conserving surgery. Currently, disease-free survival (DFS) is considered to be an
...
EMA: Draft guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission
08.05.2014
Guidance is provided on data requirements for process validation of biotechnology-derived proteins used as active substance in the manufacture of medicinal products. This guideline covers process
...
GMP: Clinical Trials Regulation adopted in Parliament
08.05.2014
The new EU Clinical Trials Regulation has recently passed the EU Parliament. The objective of the new document was to simplify the authorisation procedures for multinational clinical trials. ...
EMA: EMA guidance for companies requesting classification as MUMS/limited market
24.04.2014
This guidance document addresses a number of questions that applicants requesting classification of products for minor use or minor species (MUMS) or for limited market may have. The Committee for
...
